These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 12817772)
1. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective. Rosenblatt M J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772 [TBL] [Abstract][Full Text] [Related]
2. Study design in osteoporosis: a European perspective. Kanis JA; Alexandre JM; Bone HG; Abadie E; Brasseur D; Chassany O; Durrleman S; Lekkerkerker JF; Caulin F J Bone Miner Res; 2003 Jun; 18(6):1133-8. PubMed ID: 12817770 [TBL] [Abstract][Full Text] [Related]
3. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? Brody BA; Dickey N; Ellenberg SS; Heaney RP; Levine RJ; O'Brien RL; Purtilo RB; Weijer C J Bone Miner Res; 2003 Jun; 18(6):1105-9. PubMed ID: 12817764 [TBL] [Abstract][Full Text] [Related]
4. Is it ethical to use placebos in osteoporosis trials? Ragi-Eis S; Zerbini CA; Provenza JR; Griz LH; de Gregório LH; Russo LA; Silva NA; Borges JL; de Souza AC; Castro ML; Lewiecki EM J Clin Densitom; 2006; 9(3):274-80. PubMed ID: 16931344 [TBL] [Abstract][Full Text] [Related]
5. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis. Pak CY; Adams-Huet B; Sakhaee K; Bell NH; Licata A; Johnston C; Rubin B; Bonnick S; Piziak V; Graham H; Ballard J; Berger R; Fears W; Breslau N; Rubin C J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339 [TBL] [Abstract][Full Text] [Related]
6. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). Silverman SL; Cummings SR; Watts NB; J Bone Miner Res; 2008 Jan; 23(1):159-65. PubMed ID: 17892379 [TBL] [Abstract][Full Text] [Related]
7. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Brixen KT; Christensen PM; Ejersted C; Langdahl BL Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497 [TBL] [Abstract][Full Text] [Related]
8. The ethics of placebo-controlled trials: the case of asthma. Onder RF J Allergy Clin Immunol; 2005 Jun; 115(6):1228-34. PubMed ID: 15940139 [TBL] [Abstract][Full Text] [Related]
9. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. Seibel MJ; Naganathan V; Barton I; Grauer A J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403 [TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171 [TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
12. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. McCloskey EV; Beneton M; Charlesworth D; Kayan K; deTakats D; Dey A; Orgee J; Ashford R; Forster M; Cliffe J; Kersh L; Brazier J; Nichol J; Aropuu S; Jalava T; Kanis JA J Bone Miner Res; 2007 Jan; 22(1):135-41. PubMed ID: 17042717 [TBL] [Abstract][Full Text] [Related]
14. [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis]. Lamy O; Krieg MA Rev Med Suisse Romande; 2002 Aug; 122(8):377-81. PubMed ID: 12357730 [TBL] [Abstract][Full Text] [Related]
15. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
16. Placebo controls in clinical trials of new therapies for osteoporosis. Levine RJ J Bone Miner Res; 2003 Jun; 18(6):1154-9. PubMed ID: 12817775 [No Abstract] [Full Text] [Related]
17. Current and investigational approaches for reversing established osteoporosis. Kimmel DB; Slovik DM; Lane NE Rheum Dis Clin North Am; 1994 Aug; 20(3):735-58. PubMed ID: 7984787 [TBL] [Abstract][Full Text] [Related]
18. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D; J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study. Katz KA; Karlawish JH; Chiang DS; Bognet RA; Propert KJ; Margolis DJ J Am Acad Dermatol; 2006 Nov; 55(5):814-22. PubMed ID: 17052487 [TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]